Across TCGA pan-cancer cohorts, OCLN mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated OCLN data layer compared with 18 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher OCLN mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated OCLN expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where OCLN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	III,IV	0.838	0.203	.004	21	view →
HNSC	OS	Median	IV	0.861	0.625	.009	14	view →
LUAD	OS	Median	II,III,IV	0.807	0.461	.006	12	view →
GBM	OS	Tertile	All	0.478	0.257	.010	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: OCLN tumor-vs-normal RNA expression · all OCLN data types